Abril-Junio 2018 74
ISSN 1317-987X
 
Buscar




Artículos
 



Anatomía Patológica
Expresión Inmunohistoquímica del Antígeno Ki-67 en Relación con el Grado Histológico y Riesgo de Recidivas en Meningiomas Intracraneanos

Bibliografía

  1. Lantos PL, VanderBerg SR, Kleihues P. Tumours of the nervous system. In: Graham DI, Lantos PL, editors. Greenfield´s neuropathology. London: Arnold, 1996: 583-879.
  2. Kepes JJ. Meningiomas. Biology, pathology, and differential diagnosis. New York: Masson Monographs in Diagnostic Pathology, 1982.
  3. Burger PC, Scheithauer BW. Tumors of the central nervous system. Washington DC: Armed Forces Institute of Pathology (AFIP), 1994.
  4. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. “Malignancy” in meningiomas. A clinicopathologic study of 116 patients, with grading implications. Cancer 1999; 85: 2046-2056.
  5. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumors of the nervous system. World Health Organization Classification of Tumors. Lyon: International Agency for Research on Cancer (IARC), 2000: 175-184.
  6. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the nervous system and its coverings. Fourth edition. New York: Churchill Livingstone, 2002: 49-71.
  7. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225.
  8. Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 1997; 793-800.
  9. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 1997; 21: 1455-1465.
  10. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracraneal meningiomas with a 6 year mean follow-up. Pathol Res Pract 2000; 196: 483-488.
  11. Niedermayer I, Kolles H, Zang KD, Feiden W. Characterization of intermediate type (WHO “atypical”) meningiomas. Clin Neuropathol 1996; 15: 330-336.
  12. Otamendi VA. Meningiomas: factores pronósticos [trabajo especial de investigación para optar al título de especialista en anatomía patológica]. Caracas: Universidad Central de Venezuela, 1987.
  13. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986; 26: 461-469.
  14. Arumi M, Alameda F, Galit E, Serrano S. Value of AgNORS in predicting behaviour of meningioma. Electron J Pathol Histol 1996; 2: 21-27.
  15. Demirtas E, Yilmaz F, Ovul I, Oner K, Laerum OD. Recurrence of meningiomas versus proliferating cell nuclear antigen (PCNA) positivity and AgNOR counting. Acta Neurochir 1996; 138: 1456-1463.
  16. De Stefano V, Salvatore G, Monticelli A, Riccio P, Cappabianca P, Bucciero A. Prognostic significance of nucleolar organizer regions in meningiomas. J Neurosurg Sci 1996; 40: 89-92.
  17. Striepecke E, Handt S, Weis J, Koch A, Cremerius U, Reineke T, et al. Correlation of histology, cytogenetics and proliferation fraction (Ki-67 and PCNA) quantitated by image analysis in meningiomas. Path Res Pract 1996; 192: 816-824.
  18. Madsen C, Schroder HD. Ki-67 immunoreactivity in meningiomas-determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67. Clin Neuropathol 1997; 16: 137-142.
  19. Moller ML, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol 1997; 34: 241-246.
  20. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol 1998; 29: 1420-1427.
  21. Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med 1999; 123: 793-800.
  22. Nakaguchi H, Fujimaki T, Matsuno A, Matsuura R, Asai A, Suzuki I, et al. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer 1999; 85: 2249-2254.
  23. Choong HK, Jin HC, Koang HB, Jae MK, Suck JO. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas. J Clin Neurosci 2001; 8 Suppl 1: 44-48.
  24. Kim CH, Cheong JH, Bak KH, Kim JM,, Oh SJ. Expression of the proliferating cell nuclear antigen and clinicopathlogical features in intrancranial meningiomas. J Clin Neurosci 2001; 8 Suppl 1: 44-48.
  25. Nakasu S, Hou Li D, Okabe H, Nakajima M, Matsuda M. Significance of MIB-1 staining indices in meningiomas: comparison of two counting methods. Am J Surg Pathol 2001; 25: 472-478.
  26. Sandberg DI, Edgar MA, Resh L, Rutka JT, Becker LE, Souweidane MM, et al. MIB-1 staining index of pediatric meningiomas. Neurosurgery 2001; 48: 590-595.
  27. Torp SH, Lindboe CF, Granli US, Moen TM, Nordtomme T. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas. Clin Neuropathol 2001; 20: 190-195.
  28. Ho DMT, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas. A proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002; 94: 1538-1547.
  29. Maier H, Wanschitz J, Sedivy R, Rossler K, Ofner D, Budka H. Proliferation and DNA fragmentation in meningiomas subtypes. Neuropathol Appl Neurobiol 1997; 23: 496-506.
  30. Ng H-K, Chen L. Apoptosis is associated with atypical or malignant change in meningiomas. An in situ labelling and immunohistochemical study. Histopathology 1998; 33: 64-70.
  31. Abramovich CM, Prayson RA. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Am J Clin Pathol 2000; 114: 84-92.
  32. Konstantinidou A, Korkolopoulou P, Patsouris E, Mahera H, Hranioti S, Kotsiakis X, et al. Apoptosis detected with monoclonal antibody to single-stranded DNA is a predictor of recurrence in intracranial meningiomas. J Neurooncol 2001; 55: 1-9.
  33. Weisberg S, Ashkenazi E, Israel Z, Attia M, Shoshan Y, Umansky F, et al. Anaplastic and atypical meningiomas express high levels of Fas and undergo apoptosis in response to Fas ligation. Am J Pathol 2001; 159: 1193-1197.
  34. Verheijen FM, Donker GH, Viera CS, Sprong M, Jacobs HM, Blaauw G, et al. Progesterone receptor, bcl-2 and bax expression in meningiomas. Neurooncol 2002; 56: 35-41.
  35. Speirs V, Boyle-Walsh E, Fraser WD. Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 1997; 72: 714-719.
  36. Tonn JC, Ott MM, Bouterfa H, Kerkau S, Kapp M, Müller-Hermelink HK, et al. Inverse correlation of cell proliferation and expression of progesterone receptors in tumor spheroids and monolayer cultures of human meningiomas. Neurosurgery 1997; 41: 1152-1159.
  37. Durmaz R, Deliorman S, Isiksoy S, Uyar R, Tel E. Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro. Arch Physiol Biochem 1999; 107: 286-291.
  38. Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven WF, Thijssen JHH. Ocurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids 2000; 65: 795-800.
  39. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000; 59: 872-879.
  40. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst(2A). Clin Cancer Res 2000; 6: 1865-1874.
  41. Chen J, Chen G. Expression of androgen receptor in meningiomas. J Tongji Med Univ 2001; 21: 140-142.
  42. Verheijen FM, Sprong M, Jacobs HM, Donker GH, Amelink GJ, Thijssen JHH, et al. Progesterone receptor isoform expression in human meningiomas. Eur J Cancer 2001; 37: 1488-1495.
  43. Gursan N, Gundogdu C, Albayrak A, Kabalar ME. Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Int J Neurosci 2002; 112: 463-470.
  44. Strik HM, Strobelt I, Pietsch-Breitfeld B, Iglesias-Rozas JR, Will B, Meyermann R. The impact of progesterone receptor expression on relapse in the long-term clinical course of 93 benign meningiomas. In Vivo 2002; 16: 265-270.
  45. Taddei GL, Caldarella A, Raspollini MR, Taddei A, Buccoliero AM. Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations. Pathologica 2002; 94: 10-15.
  46. Strojnik T, Zidanik B, Kos J, Lah TT, Kaye AH, Piepmeier JM. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery 2001; 48: 598-605.
  47. Hsu DW, Efird JT, Hedley-Whyte ET. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 1998; 24: 441-452.
  48. Halper J, Jung C, Perry A, Suliman H, Hill MP, Scheithauer B. Expression of TGF alpha in meningiomas. J Neuro Oncol 1999; 45: 127-134.
  49. Lamszus K, Lengler U, Schmidt NO, Stavrou D, Ergun S, Westphal M, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000; 46: 938-948.
  50. Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci 2001; 8 Suppl 1: 49-53.
  51. Tsai JC, Hsiao YY, Teng LJ, Shun CT, Chen CT, Goldman CK, et al. Regulation of vascular endothelial growth factor secretion in human meningioma cells. J Formos Med Assoc 1999; 98: 111-117.
  52. Shono T, Inamura T, Torisu M, Suzuki SO, Fukui M. Vascular endothelial growth factor and malignant transformation of a meningioma: case report. Neurol Res 2000; 22: 189-193.
  53. Debiec-Rychter M, Biernat W, Limon J, Kordek R, Izycka E, Borowska-Lehman J, et al. Cytogenetic and proliferatative potentials in meningiomas. Pol J Pathol 1999; 50: 243-248.
  54. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, Westphal M. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999; 110: 103-110.
  55. Cerda NM, Lopez GC, Perez BM, Barcia SJL, Llombart BA. Histopathological and cytogenetic findings en benign, atypical and anaplastic human meningiomas: a study of 60 tumors. Clin Neuropathol 2000; 19: 259-267.
  56. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is and important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000; 9: 1495-1500.
  57. Joachim T, Ram Z, Rappaport ZH, Simon M, Schramm J, Wiestler OD, et al. Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. Int J Cancer 2001; 94: 218-221.
  58. Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 2001: 93: 207-220.
  59. Morrison CD, Prayson RA. Immunohistochemistry in the diagnosis of neoplasms of the central nervous system. Sem Diagn Pathol 2000; 17: 204-215.
  60. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol (Berl) 1996; 91: 504-510.
  61. Miyagami M, Kanou T, Nakamura S. P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas [Article in Japanese]. No To Shinkei 1996; 48: 719-725.
  62. Takeuchi H, Kubota T, Kabuto M, Kitai R, Nozaki J, Yamashita J. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. Surg Neurol 1997; 48: 501-506.
  63. Kakinuma K, Tanaka R, Onda K, Takahashi H. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time. Acta Neurochir (Wien) 1998; 140: 26-31.
  64. Karamitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998; 29: 140-145.
  65. Hakin-Smith V, Battersby RD, Maltby EL, Timperley WR, Royds JA. Elevated p53 expression in benign meningiomas protects against recurrence and may be indicative of senescence. Neuropathol Appl Neurobiol 2001; 27: 40-49.
  66. Greiner M. Two-graph receiver operating characteristic (TG-ROC): a Microsoft-EXCEL template for the selection of cut-off values in diagnostic test. J Immnunol Meth 1995; 185: 145-146.
  67. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol 2001; 32: 970-975.
  68. Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien) 2004; 146: 37-44.
  69. Kamei Y, Watanabe M, Nakayama T, Kanamaru K, Waga S, Shiraishi T. Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas. J Neurooncol 2000; 46: 205-213.
  70. Takahashi JA, Ueba T, Hashimoto N, Nakashima Y, Katsuki N. The combination of mitotic and KI-67 indices as a useful method for predicting short-term recurrence of meningiomas. Surg Neurol 2004; 61: 149-55.
  71. Nakasu S, Nakajima M, Handa J. The difference of MIB-1 staining indices in meningiomas by a counting method. Jpn J Neurosurg 1998; 7: 279-283.
  72. Devaprasath A, Chacko G. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas. Neurol India 2003; 51: 336-340.
  73. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. Cancer 1998; 82: 2262-2269.

Expresión Inmunohistoquímica del Antígeno Ki-67 en Relación con el Grado Histológico y Riesgo de Recidivas en Meningiomas Intracraneanos
Introducción
Población y métodos
Resultados
Discusión
Bibliografía

NOTA: Toda la información que se brinda en este artículo es de carácter investigativo y con fines académicos y de actualización para estudiantes y profesionales de la salud. En ningún caso es de carácter general ni sustituye el asesoramiento de un médico. Ante cualquier duda que pueda tener sobre su estado de salud, consulte con su médico o especialista.





Instituto de Medicina Tropical - Facultad de Medicina - Universidad Central de Venezuela.
Elaborado por el Centro de Análisis de Imágenes Biomédicas Computarizadas CAIBCO,
caibco@ucv.ve
Este portal ha sido desarrollado gracias al apoyo del Fonacit